Orasis Pharmaceuticals

About

Orasis Pharmaceuticals developed Qlosi™, an FDA approved corrective eye drop for the treatment of presbyopia in adults. Presbyopia is the gradual loss of an eye’s ability to focus on near objects, which begins to affect most people sometime after the age of 40 and affects more than 1.8 billion people worldwide. Orasis is led by a collaborative team of industry executives and eye care professionals with a broad range of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development. Orasis is funded by a diverse group of sophisticated and experienced life science and healthcare investors.